National investigation into NHS maternity services launched after families 'gaslit'
The announcement comes after Health Secretary Wes Streeting met families who have lost babies and amid the ongoing investigations at some trusts into maternity care failings.
The investigation in England is intended to provide truth to families suffering harm, as well as driving urgent improvements to care and safety, as part of efforts to ensure "no parent or baby is ever let down again".
Politics latest:
The Royal College of Midwives (RCM) welcomed the government's announcement and said maternity services were "at, or even beyond, breaking point".
Last week, the NHS regulator said maternity and neonatal services at over safety issues.
Mr Streeting, who was speaking at the Royal College of Obstetricians and Gynaecologists (RCOG) conference in London, apologised on behalf of the NHS for what families had been through and said it was "clear something is going wrong".
He added: "For the past year, I have been meeting bereaved families from across the country who have lost babies or suffered serious harm during what should have been the most joyful time in their lives.
"What they have experienced is devastating - deeply painful stories of trauma, loss, and a lack of basic compassion - caused by failures in NHS maternity care that should never have happened.
"Their bravery in speaking out has made it clear: we must act - and we must act now."
Mr Streeting said families have had to "fight for truth and justice" and had described being "ignored, gaslit, lied to, manipulated and damaged further by the inability for a trust to simply be honest with them that something has gone wrong".
The investigation will consist of two parts.
The first will investigate up to 10 of the most concerning maternity and neonatal units, including Sussex, in the coming weeks to give affected families answers as quickly as possible, according to the Department of Health.
The second will be a "system-wide" look at maternity and neonatal care, uniting lessons from past inquiries to create one clear set of actions designed to improve NHS care.
A National Maternity and Neonatal Taskforce will be chaired by Mr Streeting and made up of experts and bereaved families.
The investigation will begin this summer and report back by December.
Sir Jim Mackey, chief executive of NHS England, said: "This rapid national investigation must mark a line in the sand for maternity care - setting out one set of clear actions for NHS leaders to ensure high quality care for all."
Dr Ranee Thakar, president of the RCOG, said: "The maternity workforce is on its knees, with many now leaving the profession."
Read more from Sky News:
RCM chief executive Gill Walton said: "Everyone involved in maternity services - the midwifery community, obstetricians, anaesthetists, sonographers and, of course, the women and families in their care - knows that maternity services are at, or even beyond, breaking point.
"This renewed focus and commitment by the health secretary to deliver change is welcome, and we will do everything we can to support him in doing so."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
12 minutes ago
- Associated Press
Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress
Wuppertal, Germany, August 5, 2025 - Aicuris Anti-infective Cures AG today announced initial clinical data from its ongoing first-in-human Phase 1 trial with AIC468. The novel antiviral antisense oligonucleotide is in development for the treatment of BK virus (BKV) infections in kidney transplant recipients. The interim results, presented at the World Transplant Congress in San Francisco on August 4, 2025, provide an overview of PK characteristics of AIC468 from the Phase 1 clinical trial in healthy volunteers. 'BK virus infections represent a serious and persistent threat for immunocompromised patients with a high risk of renal damage or kidney loss after transplantation. The PK results and safety data to date are very encouraging and provide us with valuable insights for the continued development of this differentiated program,' said Cynthia Wat, MD, CMO of Aicuris. 'Our goal is to achieve tangible therapeutic solutions for immunocompromised patients with kidney transplants, and these strong PK and safety data are an important step for us in achieving this goal.' FIH trial data from 72 healthy volunteer subjects, six single ascending dose (SAD) subcutaneous cohorts, one intravenous dose level and two multiple ascending dose (MAD) subcutaneous cohorts were presented at World Transplant Congress. AIC468 was safe and well tolerated across all cohorts investigated to date. The product candidate achieved excellent bioavailability (82%), rapid absorption, and distribution to peripheral tissues. A favorable half-life together with pre-clinical data, suggests that efficacious kidney concentrations can be attained by weekly or less frequent dosing regimens within the investigated dose range. Additionally, renal clearance for AIC468 accounted for less than 2% of the total clearance, representing a negligible route of elimination. Tissue uptake and subsequent metabolism appear to be the primary route of clearance, supporting the observed benign safety profile. The trial is progressing as planned in the third MAD cohort. 'Aicuris continues to build momentum by executing on our clinical trial strategy and achieving the first positive data set for our third clinical program for immunocompromised patients,' added Larry Edwards, CEO of Aicuris. 'In the second half of 2025 we expect data from the Phase 1 program to allow us to rapidly advance AIC468 into a Phase 2a proof-of-mechanism trial in H1 2026 to demonstrate its value for patients.' The randomized, double-blind, placebo-controlled first-in-human trial ( 2023-510074-13-00 ) is designed to evaluate the safety, tolerability and pharmacokinetics of AIC468 in healthy volunteers. SAD cohorts tested AIC468 or a placebo control in a total of 56 healthy volunteers across six subcutaneous (25 mg to 600 mg) and one intravenous dose level (200 mg). In the MAD cohorts an additional 24 subjects receive five repeated doses of AIC468 (130 mg, 230mg and 330 mg). Dosing in all SAD and the first two MAD cohorts have been successfully completed. The trial is progressing as planned in the third MAD cohort with data expected later this year. About BKV BKV is a ubiquitous polyomavirus that infects most people in early childhood, typically without symptoms. In immunocompromised individuals, such as organ transplant recipients, BKV can reactivate, leading to serious health issues. In kidney transplant patients, BKV reactivation can cause BK virus-associated nephropathy (BKVAN), affecting up to 10% of recipients and potentially resulting in graft loss. Current management involves reducing immunosuppressive therapy, which increases the risk of graft rejection. Despite its prevalence, there is no approved antiviral treatment specifically for BKV. About AIC468 AIC468 is an antisense oligonucleotide therapy designed to treat BK virus reactivation in kidney transplant patients which can pose a significant health risk for these patients. The candidate blocks viral replication within infected cells by inhibiting splicing of the pre-mRNA that encodes for the virus' large T-antigen. This innovative approach has already demonstrated potent antiviral activity along with a favorable pharmacokinetic and safety profile in preclinical studies and is currently being evaluated in a Phase 1 clinical trial. About Aicuris Aicuris is meeting the needs of the growing population of immunocompromised people who require precise therapies to effectively treat infection. Our flagship product, PREVYMIS®, marketed by our partner MSD, prevents CMV in a defined group of transplant recipients. Our pivotal Phase 3 candidate, pritelivir, aims to address refractory HSV infections in a broad population of patients with weakened immune systems. For immunocompromised people, an otherwise manageable infection can mean life or death. Aicuris, with its expertise and growing pipeline, is committed to providing therapeutic solutions for them now and in the future. Contact: Aicuris Anti-infective Cures AG [email protected] Trophic Communications Dr. Stephanie May and Dr. Charlotte Spitz Phone: +49 171 3512733 Email: [email protected]
Yahoo
an hour ago
- Yahoo
New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference
STOCKHOLM, SE / / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that an abstract about the preclinical project TrkA-NAM ACD137 against osteoarthritis and other severe pain conditions has been accepted for presentation at the international pain conference NeuPSIG 2025, to be held in Berlin, Germany, September 4-6. The abstract, titled Analgesic and anti-inflammatory effects of ACD137, a potent and selective negative allosteric modulator of TrkA , will be presented at NeuPSIG 2025 by Märta Segerdal, Head of Development and Chief Medical Officer at AlzeCure Pharma. Co-authors are Pontus Forsell, Maria Backlund, Veronica Lidell, Azita Rasti, Cristina Parrado-Fernandez, Johan Sandin and Gunnar Nordvall. The results show that the lead drug candidate in the project, ACD137, has potent analgesic effects in several different preclinical pain models. The analgesic effect of ACD137 in the study was as potent as the effect of the anti-NGF antibody Tanezumab, which has demonstrated significant and robust pain relief in several clinical trials. ACD137 achieves its effect by blocking NGF-mediated signaling via TrkA receptors, a biological mechanism with strong genetic, preclinical and clinical validation for its role in pain. These positive preclinical data in models of osteoarthritis, neuropathic pain and nociceptive pain further strengthen previous positive analgesic results obtained with ACD137 and further underline its broad applicability in various severe pain conditions, including osteoarthritis. "These data demonstrate that our drug candidate ACD137 is a highly potent and selective TrkA-NAM that exhibits significant analgesic effects in relevant preclinical animal models. Furthermore, this small molecule TrkA-NAM has the potential to avoid some of the side effects observed with anti-NGF antibodies due to a more selective mechanism of action, while maintaining analgesic efficacy," said Pontus Forsell, project leader and Head of Discovery and Research at AlzeCure Pharma. "The project is based on a mechanism with strong validation, both preclinically and clinically. The results we have for TrkA-NAM in pain are promising, and the fact that we also have anti-inflammatory effects with our substance opens up for broader application. The fact that this is also a mechanism that is not linked to the side effects and addiction problems observed with opioids and antibodies is of course also important for a potential future approval," said Martin Jönsson, CEO of AlzeCure Pharma AB. The abstract and the poster will be available on AlzeCure's website after the presentation ( For more information, please contact Martin Jönsson, CEOTel: +46 707 86 94 About AlzeCure Pharma AB (publ) AlzeCure ® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore ® , Alzstatin ® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit About TrkA-NAMThe TrkA-NAM project, which is in research phase, is focused on the treatment of pain. The target mechanism, NGF / TrkA signaling, is well-validated both preclinically and clinically and provides a promising alternative to new analgesics without the side effects and addiction problems observed with opioids. Substances developed in the project have recently been shown to also have anti-inflammatory properties. For the TrkA-NAM drug project, we have leveraged our knowledge concerning the underlying biology for the NeuroRestore platform in order to develop new compounds that focus on providing pain relief in conditions associated with severe pain. The goal of the project is to develop a small-molecule TrkA-negative allosteric modulator for the treatment of osteoarthritis pain and other severe pain disorders. The global osteoarthritis market is expected to reach USD 11.0 billion by 2025, from USD 7.3 billion in 2020. Growth in this market is driven by factors such as the increasing occurrence of osteoarthritis, the growing aging population, and an increase in the number of sports injuries. Over 400 million people worldwide suffer from painful and activity-limiting osteoarthritis of the hip or knee. Many patients experience insufficient pain relief or side effects with current treatment, which today usually consist of NSAIDs or opiates and there is a great need for more effective and better tolerated drugs in this field. Read more about TrkA-NAM on our homepage. Image Attachments Martin Jönsson CEO And Pontus Forsell Head Of D&R AlzeCure Pharma Attachments New scientific data with TrkA-NAM ACD137 against knee osteoarthritis to be presented at pain conference SOURCE: AlzeCure Pharma View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
an hour ago
- Medscape
Ketamine's Antidepressant Action May Depend on Opioid System
Activation of the body's opioid system may be required for ketamine's antidepressant effects, new research hinted. In a small study of adults with major depressive disorder, taking the opioid blocker naltrexone before a low-dose ketamine infusion both blunted the surge in glutamate — a key brain chemical linked to mood — and reduced ketamine's rapid antidepressant benefit the next day. 'These results suggest that opioid receptors help mediate ketamine's effects and that blocking opioid receptors may lessen ketamine's acute mood-lifting action,' lead researcher Luke Jelen, MBBS, clinical lecturer in psychiatry, King's College London, London, England, told Medscape Medical News . 'However, this was a small, mechanistic study, not a treatment trial, so there is no immediate indication to change clinical practice or avoid naltrexone. Larger, dedicated clinical studies are required before recommending any alteration to current protocols,' Jelen cautioned. The study was published online on July 24 in Nature Medicine . New Mechanistic Insights Ketamine's rapid-acting antidepressant effects are thought to work by transiently elevating glutamate in the anterior cingulate cortex and other frontal regions, setting off a cascade of plasticity-related pathways. Prior animal and small human studies have suggested that activating mu-opioid receptors might be necessary for ketamine's mood benefits. To investigate, Jelen and colleagues enrolled 26 adults with moderate-to-severe depression in a randomized double-blind crossover trial separated by 3 weeks. Participants received either oral placebo or 50 mg naltrexone 1 hour before receiving intravenous ketamine (0.5 mg/kg). During the first 30 minutes of each infusion, they measured brain glutamatergic activity in the anterior cingulate cortex using functional magnetic resonance spectroscopy. Depressive symptoms were measured before and 24 hours after infusion, when ketamine's antidepressant effects peak, using the Montgomery-Åsberg Depression Rating Scale (MADRS). Compared with placebo, pretreatment with a single 50-mg dose of oral naltrexone reduced the brain's glutamatergic response and dampened the average improvement on MADRS measured 24 hours later, the researchers observed. Specifically, the glutamate signal climbed significantly during ketamine when participants had taken placebo, but the rise was significantly smaller when they had taken naltrexone ( P = .029; Cohen's d = 0.34). 'We also identified a sex-related effect: The attenuating effect of naltrexone on glutamate activity appeared more pronounced in males with depression than in females with depression,' Jelen said. Alongside the attenuation of ketamine-induced glutamatergic activity, naltrexone pretreatment also led to less marked reductions in clinician-rated MADRS scores 24 hours after infusion — equating to a 28% attenuation in the main effect of ketamine ( P = .023), the researchers reported. Reductions in self-reported depressive measures were numerically lower in the presence of naltrexone than in the presence of placebo, but the differences were not statistically significant. 'The possibility of an opioid mechanism underlying the antidepressant mechanisms of ketamine has been a recent subject of considerable debate. Our study provides evidence that opioid system activation may contribute to the acute antidepressant effects of ketamine,' the authors wrote. Looking ahead, Jelen told Medscape Medical News , a larger, well-powered study should include a true placebo-infusion arm to disentangle naltrexone's effects on both ketamine and placebo responses. He also noted that adding PET imaging would directly quantify opioid-receptor engagement, and prespecified analyses by sex are essential, given the stronger glutamate-dampening effect observed in men. 'Understanding more about how ketamine works can lead to treatment being personalized for different people, which is vital for creating safe and effective treatments,' Jelen said.
